Proliferative Vitreoretinopathy - Pipeline Insight, 2024

This “Proliferative vitreoretinopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Proliferative vitreoretinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Proliferative vitreoretinopathy Understanding

Proliferative vitreoretinopathy: Overview

Proliferative vitreoretinopathy (PVR) is a rare ocular condition that can lead to vision loss or blindness. It occurs after retinal detachment repair surgery or as a result of an open globe injury (trauma to the eyeball). When a person develops PVR, cells in the retina start to multiply and form scar tissue. The scar tightens and pulls the retina away. There is no approved therapy for PVR, which accounts for 75% of complications following retinal detachment, and occurs in 5 to 10% of people after having retinal attachment surgery. PVR also occurs in up to 50% of people who have suffered an open globe injury.

Proliferative vitreoretinopathy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proliferative vitreoretinopathy pipeline landscape is provided which includes the disease overview and Proliferative vitreoretinopathy treatment guidelines. The assessment part of the report embraces, in depth Proliferative vitreoretinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proliferative vitreoretinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Proliferative vitreoretinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Proliferative vitreoretinopathy.

Proliferative vitreoretinopathy Emerging Drugs Chapters

This segment of the Proliferative vitreoretinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Proliferative vitreoretinopathy Emerging Drugs

ADX-2191: Aldeyra TherapeuticsADX-2191, an intravitreal formulation of methotrexate, has been granted orphan drug designation for the prevention of proliferative vitreoretinopathy (PVR). The observed clinical activity of ADX-2191 in patients with PVR is believed to be the result of down-regulation of aberrant retinal cell proliferation and activity, thereby leading to reduced retinal scarring that is characteristic of PVR. Aldeyra retains an exclusive license to certain patents related to the use of ADX-2191 for the prevention of PVR.

PPP-003: Tetra Bio-PharmaPPP003 (HU308) is a synthetic cannabinoid. This ophthalmic drug is currently under preclinical development and has received U.S. Food and Drug Administration Orphan Drug Designation for the prevention of proliferative vitreoretinopathy.

Proliferative vitreoretinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Proliferative vitreoretinopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Proliferative vitreoretinopathy

There are approx. 3+ key companies which are developing the therapies for Proliferative vitreoretinopathy. The companies which have their Proliferative vitreoretinopathy drug candidates in the most advanced stage, i.e. phase III include, Aldeyra Therapeutics.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Proliferative vitreoretinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proliferative vitreoretinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proliferative vitreoretinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proliferative vitreoretinopathy drugs.

Proliferative vitreoretinopathy Report Insights

• Proliferative vitreoretinopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Proliferative vitreoretinopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Proliferative vitreoretinopathy drugs?
• How many Proliferative vitreoretinopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proliferative vitreoretinopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Proliferative vitreoretinopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Proliferative vitreoretinopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aldeyra Therapeutics
• Tetra Bio-Pharma
• Aviceda Therapeutics

Key Products

• ADX-2191
• PPP-003
• AVD 201

This product will be delivered within 2 business days.